In a filing, Angiodynamic Inc revealed its President and CEO Clemmer James C acquired Company’s shares for reported $67000.0 on Apr 08 ’24. In the deal valued at $6.70 per share,10,000 shares were bought. As a result of this transaction, Clemmer James C now holds 539,066 shares worth roughly $3.25 million.
Oppenheimer upgraded its Angiodynamic Inc [ANGO] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late September with a ‘”a Buy”‘ rating. Raymond James also remained covering ANGO and has decreased its forecast on April 17, 2023 with a “an Outperform” recommendation from previously “Strong buy” rating. Canaccord Genuity revised its rating on October 15, 2021. It rated ANGO as “a Buy” which previously was an “a Hold”.
Price Performance Review of ANGO
On Tuesday, Angiodynamic Inc [NASDAQ:ANGO] saw its stock fall -3.67% to $6.03. Over the last five days, the stock has lost -7.37%. Angiodynamic Inc shares have fallen nearly -23.09% since the year began. Nevertheless, the stocks have fallen -32.25% over the past one year. While a 52-week high of $11.38 was reached on 01/02/24, a 52-week low of $5.26 was recorded on 03/25/24. SMA at 50 days reached $5.94, while 200 days put it at $6.97. A total of 0.38 million shares were traded, compared to the trading of 0.34 million shares in the previous session.
Levels Of Support And Resistance For ANGO Stock
The 24-hour chart illustrates a support level at 5.92, which if violated will result in even more drops to 5.81. On the upside, there is a resistance level at 6.22. A further resistance level may holdings at 6.41. The Relative Strength Index (RSI) on the 14-day chart is 46.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.07%. Stochastics %K at 13.87% indicates the stock is a buying.
The most recent change occurred on August 20, 2021 when Oppenheimer began covering the stock and recommended ‘”a Perform”‘ rating.
